Redx Pharma Share Discussion Threads

[molatovkid] 02/6/2015 09:45

You dont need to be. MRSA is a worldwide problem, if this is the answer, the major pharmas will be queuing up to licence it.

[mirabeau] 02/6/2015 09:40

Moving away now

I do like the word 'breakthrough' used in the RNS. It does appear to represent a significant step forward though I'm no pharmacologist so pls ignore my ill-informed musings

[molatovkid] 02/6/2015 08:27

Reading between the lines, they sound very confident in this latest discovery....wonder what sort of results it has been showing thus far

[whitebicycle] 01/6/2015 11:56

Mirabeau sit back and relax.
I thought of doubling up a week or so ago but decided on Quantum Pharma QP. instead.
15 years ago I took a punt on AMS @ 9p, now a 15 bagger paying a divi. Elan Corp ELN was another, that was a roller coaster of a ride but came good in the end as it is now Perrigo PRGO fighting off a bid from Mylan.
I've had a few dogs along the way, fraud being behind most of them.

They only need to get lucky once.

[mirabeau] 01/6/2015 11:39

Looking strong again

[mirabeau] 29/5/2015 14:27

£45k and £23k buys

[mirabeau] 29/5/2015 13:09

I knew this would come good even if it is a tad high risk.

[mirabeau] 14/5/2015 07:37

Appears to be building up a head of steam in a hot sector but the caveat is glaringly obvious even to the most naive of investors. The stock is as high a risk as it is possible to achieve

[whitebicycle] 27/3/2015 13:20

Took a small punt just after the open after reading the Liverpool Echo article last night.
It might be the next 10 bagger but just as likely to burn through the cash before any results come through.
I've been here before and would rather be in than out.
DYOR.

[proactivest] 27/3/2015 10:16

- video interview

[proactivest] 27/3/2015 10:16

Interview with Neil Murray:

[bad robot] 27/3/2015 08:54

No go, just got saxo to close at B/E :(

[bad robot] 27/3/2015 08:30

who could possibly trade at 85p? shorter with 94k? Very risky.

Lock period period here is 6month. Or someone got it from the underwriters?

[glibgibon] 27/3/2015 08:17

This equity is ineligible for the selected account.

Phooey

[bad robot] 27/3/2015 08:09

The race to 100p is about to start

[bad robot] 27/3/2015 07:57

SAXO and TD just released it

[bad robot] 27/3/2015 07:53

Ready to launch just been released

[bad robot] 27/3/2015 07:37

TIDMREDX

RNS Number : 6285I

Redx Pharma plc

27 March 2015

AIM: REDX

Redx Pharma plc

("Redx" or "the Company" or "the Group")

First Day of Dealings on AIM following GBP15 million placing

Redx, the drug discovery and development company, is pleased to announce that admission and trading of its Ordinary Shares commences today on AIM, with the ticker REDX.

Redx has placed 17,647,059 New Ordinary Shares at 85p per share to raise GBP15 million (gross). Shore Capital is acting as the Group's Nominated Adviser and Broker and acted as sole bookrunner to the Placing. At the Placing Price, Redx's market capitalisation is approximately GBP55.2 million on Admission.

KEY POINTS

-- Established in 2010, Redx is focused on improving the characteristics of existing drug classes to create highly differentiated 'best-in-class' new drugs principally in cancer and infectious disease.

-- Redx has established an extensive pipeline of proprietary drug candidates, targeting best-in-class performance, which are patent protected:

- four programmes have achieved pre-clinical proof of concept, with relevance for respective therapies to treat MRSA, bone tumours, skin, brain and blood cancers, where Redx has demonstrated superior performance to competitor drugs.

-- Redx's work to date has been endorsed by partnerships with global pharmaceutical companies and the NHS, including a two year research collaboration and option agreement with AstraZeneca UK Limited, focusing on an undisclosed oncology drug candidate, signed in August 2014.

-- Redx's business model aims to capitalise on the growing need of established large pharmaceutical companies to replenish their drug development pipelines as well as enabling emerging pharmaceutical companies to diversify their existing pipelines.

-- As Redx continues to grow, the Directors believe that the Group should have the opportunity to develop additional valuable pipeline assets in current and new therapeutic areas.

-- The net proceeds of the Placing will be used to progress the Group's current pipeline of oncology and infectious disease assets and support the launch of a third subsidiary focused on immunology.

Neil Murray, Chief Executive Officer of Redx, commented:

"I am delighted that Redx has joined AIM and, at the same time, successfully raised some GBP15m of new funding. The Company is now embarking on the next stage of its development and we believe that prospects are exciting.

Our business model is to improve on existing drug classes and to partner early, and in doing so establish Redx as a highly attractive pipeline generator for large pharma and emerging life science companies. We already have a pipeline of potential drug candidates, with our focus on areas of high unmet need in cancer and infection. The new funds we have raised will support the ongoing development of our pipeline as well as the launch of a third therapeutic area focused on immunology. Meanwhile our objective of the Company attaining early profitability remains."

For further information, please contact:

[bad robot] 27/3/2015 07:31

TICKER REDX

Not available till 8.00. Just spoken to them, exchange not released it yet

[keya5000] 27/3/2015 07:25

Errr try REDX perhaps, only a wild guess.

[phoenix equity] 27/3/2015 07:24

Whats the epic for this ?

[bad robot] 27/3/2015 07:22

I am going to give them a call now. I am having a ticker issue

[the infidel] 27/3/2015 07:21

Is it 8.00am they will unleash it?